Dr. Reeder and colleagues awarded highly competitive challenge grant as part of ARRA
Posted on 2009-11-02

Dr. Scott Reeder and colleagues were awarded a $1 million NIH grant through the American Recovery and Reinvestment Act to improve treatment of patients with hepatocellular carcinoma using innovative new MRI techniques. The team will use a non-invasive method that uses magnetic resonance imaging (MRI) to measure blood flow (perfusion) in hepatocellular carcinoma (HCC). The team will use the new method to determine whether anti-angiogenic drugs used to treat these tumors are effective. Currently, patients must undergo 2-3 months of anti-angiogenic therapy, which can be toxic and is expensive, in order to determine whether the drug is effective against the tumor. Using the new perfusion MRI methods, Dr. Reeder and his team aim to determine the efficacy of the drug in 2 days. In this way, the prolonged use of ineffective, toxic and expensive drugs can be avoided and alternative therapies pursued. Co-investigators include William Schelman, MD, PhD from Oncology, Sean Fain, PhD from Medical Physics and Radiology, and Wally Block, PhD from Biomedical Engineering and Radiology.

More news:

Poster recognized at UW Health Quality Week

$1 million awarded by NIMH for fMRI study

Drs. Pickhardt and Kim release new text on CT Colonography

Dr. Kanne is author on newly published High-Resolution CT of the Chest